Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nutritional High International Inc. Ordinary Shares C.NHL


Primary Symbol: SPLID

High Fusion Inc is engaged in the manufacturing, processing, and distribution of infused edible products. The company's operating and geographical segments include Palo Verde; Pasa Verde; Oregon; Colorado; Nevada and Washington. It generates maximum revenue from the Palo Verde segment.


OTCPK:SPLID - Post by User

Post by Deviouson Jan 08, 2018 11:27am
152 Views
Post# 27306310

VPT NEWS -- TRADING JUST RESUMED UP 25%

VPT NEWS -- TRADING JUST RESUMED UP 25%Toronto, Ontario / TheNewswire / January 8, 2018 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company", TSXV:VPT) is pleased to announce that it has received the European CE Mark for the VMS+ Whole Heart Analysis System, which allows the Company to begin selling the VMS+ throughout the European Union. This system uses conventional 2D ultrasound to analyse all four chambers of the heart in minutes with accuracy equivalent to MRI. "This is great news as it allows the Company to bring the capabilities of the VMS+ to cardiologists in Europe and improve cardiac care," stated Dr. George Adams, CEO of Ventripoint. "The quick acceptance of the VMS+ application is a credit to our development and regulatory groups." According to the European Heart Network, cardiovascular disease (CVD) causes 3.9 million deaths in Europe annually and accounts for 45% of all deaths in Europe. In 2015, there were just under 11.3 million new cases of CVD in Europe and more than 85 million people in Europe were living with CVD. Overall CVD is estimated to cost the European economy EUR210 billion ($300B) a year. The CE Mark is also recognized worldwide and will allow the Company to register the VMS+ in many additional regions and countries. This will greatly expand the commercial opportunities and allow distributors to sell into their regions. About Ventripoint Diagnostics Ltd. Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR) to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Corporation has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care. For further information, please contact: Dr. George Adams, CEO telephone: (519) 803-6937 email: gadams@ventripoint.ca
<< Previous
Bullboard Posts
Next >>